10 reasons why it is worth to use combined drug with timolol and dorzolamide in glaucoma therapy Review article
Article Sidebar
Published:
Dec 31, 2017
Keywords:
glaucoma, timolol, dorzolamide, fixed combination, glaucoma therapy
Main Article Content
Abstract
Primary open-angle glaucoma is one of the main causes of irreversible blindness in developed countries. It does not have distinct symptoms and remains undiagnosed until advanced stages with loss of useful visual acuity. The major risk factor of glaucoma is elevated intraocular pressure. All therapies of proven efficacy which protect optic nerve concentrate on its decreasing. Development of glaucoma pharmacotherapy is focused on introduction of new classes of hypotensive substances but also on fixed combinations of known drugs. First fixed combination released on market was timolol–dorzolamide which still has a lot of advantages for glaucoma patients.
Article Details
How to Cite
Kosior-Jarecka, E. (2017). 10 reasons why it is worth to use combined drug with timolol and dorzolamide in glaucoma therapy. Medycyna Faktow (J EBM), 10(4(37), 352-356. https://doi.org/10.24292/01.MF.0417.9
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Fechtner R.D., Realini T.: Fixed combinations of topical glaucoma medications. Curr. Opin. Ophthalmol. 2004; 15(2): 132-135.
2. Inoue K., Shiokawa M., Sugahara M. et al.: Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn. J. Ophthalmol. 2012; 56(6): 559-563.
3. Fechtner R.D., Airaksinen P.J., Getson A.J. et al.; COSOPT versus XALATAN Study Groups: Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol. Scand. 2004; 82(1): 42-48.
4. Cheng J.W., Cheng S.W., Gao L.D. et al.: Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One 2012; 7(9): e45079.
5. Crichton A.C., Harasymowycz P., Hutnik C.M. et al.: Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J. Ocul. Pharmacol. Ther. 2010; 26(5): 503-511.
6. Ormrod D., McClellan K.: Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000; 17(6): 477-496.
7. Caprioli J., Coleman A.L.: Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008; 115(7): 1123-1129.
8. Bengtsson B., Leske M.C., Hyman L., Heijl A.; Early Manifest Glaucoma Trial Group: Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(2): 205-209.
9. Kass M.A., Gordon M.O., Gao F. et al.; Ocular Hypertension Treatment Study Group: Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch. Ophthalmol. 2010; 128(3): 276-287.
10. Pasquale L.R.: Optimizing therapy for newly diagnosed open-angle glaucoma: lessons learned from the Collaborative Initial Glaucoma Treatment Study. Arch. Ophthalmol. 2008; 126(1): 125-127.
11. Noecker R., Miller K.V.: Benzalkonium chloride in glaucoma medications. Ocul. Surf. 2011; 9(3): 159-162.
12. Ayaki M., Iwasawa A., Niwano Y.: Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride. Biocontrol. Sci. 2012; 17(3): 115-120.
13. Joseph A., Pasquale L.R.: Attributes Associated with Adherence to Glaucoma Medical Therapy and its Effects on Glaucoma Outcomes: An Evidence- Based Review and Potential Strategies to Improve Adherence. Semin. Ophthalmol. 2017; 32(1): 86-90.
14. Li T., Lindsley K., Rouse B. et al.: Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology 2016; 123(1): 129-140.
15. Sena D.F., Lindsley K.: Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst. Rev. 2013; (2): CD006539.
16. Hartleben-Matkin C., Prada D., Mancilla-Vences R.: A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG. Int. J. Ophthalmol. 2014; 7(2): 330-334.
17. Tanna A.P., Lin A.B.: Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr. Opin. Ophthalmol. 2015; 26(2): 116-120.
18. Sng C.C., Ang M., Barton K.: Uveitis and glaucoma: new insights in the pathogenesis and treatment. Prog. Brain Res. 2015; 221: 243-269.
19. Turk A., Ceylan O.M., Gokce G. et al.: Comparison of brimonidine-timolol and dorzolamide-timolol in the management of intraocular pressure increase after phacoemulsification. Int. J. Ophthalmol. 2015; 8(5): 945-949.
2. Inoue K., Shiokawa M., Sugahara M. et al.: Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn. J. Ophthalmol. 2012; 56(6): 559-563.
3. Fechtner R.D., Airaksinen P.J., Getson A.J. et al.; COSOPT versus XALATAN Study Groups: Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol. Scand. 2004; 82(1): 42-48.
4. Cheng J.W., Cheng S.W., Gao L.D. et al.: Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One 2012; 7(9): e45079.
5. Crichton A.C., Harasymowycz P., Hutnik C.M. et al.: Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J. Ocul. Pharmacol. Ther. 2010; 26(5): 503-511.
6. Ormrod D., McClellan K.: Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000; 17(6): 477-496.
7. Caprioli J., Coleman A.L.: Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008; 115(7): 1123-1129.
8. Bengtsson B., Leske M.C., Hyman L., Heijl A.; Early Manifest Glaucoma Trial Group: Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(2): 205-209.
9. Kass M.A., Gordon M.O., Gao F. et al.; Ocular Hypertension Treatment Study Group: Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch. Ophthalmol. 2010; 128(3): 276-287.
10. Pasquale L.R.: Optimizing therapy for newly diagnosed open-angle glaucoma: lessons learned from the Collaborative Initial Glaucoma Treatment Study. Arch. Ophthalmol. 2008; 126(1): 125-127.
11. Noecker R., Miller K.V.: Benzalkonium chloride in glaucoma medications. Ocul. Surf. 2011; 9(3): 159-162.
12. Ayaki M., Iwasawa A., Niwano Y.: Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride. Biocontrol. Sci. 2012; 17(3): 115-120.
13. Joseph A., Pasquale L.R.: Attributes Associated with Adherence to Glaucoma Medical Therapy and its Effects on Glaucoma Outcomes: An Evidence- Based Review and Potential Strategies to Improve Adherence. Semin. Ophthalmol. 2017; 32(1): 86-90.
14. Li T., Lindsley K., Rouse B. et al.: Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology 2016; 123(1): 129-140.
15. Sena D.F., Lindsley K.: Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst. Rev. 2013; (2): CD006539.
16. Hartleben-Matkin C., Prada D., Mancilla-Vences R.: A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG. Int. J. Ophthalmol. 2014; 7(2): 330-334.
17. Tanna A.P., Lin A.B.: Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr. Opin. Ophthalmol. 2015; 26(2): 116-120.
18. Sng C.C., Ang M., Barton K.: Uveitis and glaucoma: new insights in the pathogenesis and treatment. Prog. Brain Res. 2015; 221: 243-269.
19. Turk A., Ceylan O.M., Gokce G. et al.: Comparison of brimonidine-timolol and dorzolamide-timolol in the management of intraocular pressure increase after phacoemulsification. Int. J. Ophthalmol. 2015; 8(5): 945-949.